Prometheus Biosciences, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)

This study tested a new drug called tulisokibart (PRA023) in 55 people with moderate to severe Crohn's disease. The goal was to see if the drug is safe and can improve symptoms and gut healing. Participants who finished the first 12 weeks could continue treatment for up to 170 we…